Millennium Predictive's Outcome
Millennium Pharmaceuticals' new collaboration with Roche Diagnostics to develop prognostic and therapeutic information products in rheumatoid arthritis is notable as being only the second molecular diagnostics discovery deal involving the delivery of targets to a large diagnostics company (the first being Millennium's Becton Dickinson deal in cancer). But the news behind the scenes is that Millennium has also quietly re-integrated two of the three programs in its Predictive Medicine subsidiary, setting the stage for the roll-out of a major, web-based personalized medical information play, most likely by year-end.
You may also be interested in...
Big Diagnostics Companies See the Genomics Light
Until now, large diagnostics companies have been slow to get involved in the industry's biggest paradigm shift in a decade: the move to molecular markers that will help make diagnostics part of the treatment process. At this year's AACC, the small companies leading the way in this field were beginning to make their presence felt. And the big companies, J&J, Roche, Abbott, Beckman, were starting to talk about their own programs in the field. But they're moving slowly in a fast-moving field, and thus are vulnerable to new competitors.
Travere Looks Ahead To Phase III In Homocystinuria
The latest data from a Phase I/II study shows that pegtibatinase can yield a rapid, sustained reduction in homocysteine, the protein behind the underlying cause of the rare disease.
Minute Insight: Inbound Health Now Offers Post-Surgical Hospital Care At Patients’ Homes
The hospital-to-home care movement is rising, and Inbound Health wants to be at the forefront of enabling health systems and health plans nationwide to bring hospital-level care into the home, now adding general surgery to its offerings.